Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 M1W5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTVTYV3UUN3ME21Mlg3PjZizszN MUXTRW5ITVJ?
DOHH-2 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTaW3VKSzVyPUmuN|U3QDlizszN MkPGV2FPT0WU
no-10 NYTMVJJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PKc2lEPTB;OT65NFM6KM7:TR?= M{TmNXNCVkeHUh?=
LS-513 M{fydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLEZ|lKSzVyPUGxMlM2PDdizszN NEjRSHpUSU6JRWK=
ALL-PO NHTse|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL3XolKSzVyPUGxMlc4OzRizszN M3vTVnNCVkeHUh?=
8-MG-BA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXpZpZKSzVyPUGzMlEyOjNizszN Mme5V2FPT0WU
RPMI-8402 NVuzXI9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvBTWM2OD1zNT64OVM4KM7:TR?= MXXTRW5ITVJ?
EoL-1-cell NYn2enJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH0VHo6UUN3ME2xPE42QTR6IN88US=> M1;mcXNCVkeHUh?=
NALM-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrhXlNKSzVyPUG5MlAyPjdizszN MkTHV2FPT0WU
DEL MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDKeIx3UUN3ME2yNE4yPDdzIN88US=> NGPndIhUSU6JRWK=
SR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPuOZdKSzVyPUKzMlY4OTVizszN NY\pSIRwW0GQR1XS
697 M3XjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\iTWM2OD1{Nj62NVU2KM7:TR?= MYrTRW5ITVJ?
COLO-829 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\R[WRKSzVyPUK2Mlg1QDNizszN NIDYOGtUSU6JRWK=
EVSA-T MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoOwTWM2OD1{Nz61OVYyKM7:TR?= NVfkcXpHW0GQR1XS
ATN-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TqcGlEPTB;M{GuNlMzQSEQvF2= MWXTRW5ITVJ?
L-363 NHjY[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn60TWM2OD1|MT63OFYyKM7:TR?= M4XaW3NCVkeHUh?=
LAMA-84 MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTwTWM2OD1|Mj61NlEyKM7:TR?= NXrzeY9WW0GQR1XS
NOS-1 NYfSUpZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjRTINKSzVyPUO0MlI6PTZizszN MmXOV2FPT0WU
BB30-HNC NFTi[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom1TWM2OD1|ND6zN|A3KM7:TR?= MmnXV2FPT0WU
BC-1 NUnpWlFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\JN3V[UUN3ME2zO{46PzR4IN88US=> M1LL[HNCVkeHUh?=
IST-SL2 M2S2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjZXnRPUUN3ME2zPE4zOjRizszN MlLvV2FPT0WU
D-392MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDP[WpKSzVyPUSwMlIzOTVizszN M37LVnNCVkeHUh?=
no-11 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzNTWM2OD12MD61OVIyKM7:TR?= NHrGZotUSU6JRWK=
LC4-1 M{flVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvjOpBKSzVyPUSwMlg4OTZizszN MYDTRW5ITVJ?
A388 NFHGSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH32d|hKSzVyPUSyMlU5PDhizszN NYixdotDW0GQR1XS
NTERA-S-cl-D1 NI\OTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn1coliUUN3ME20Nk44ODd2IN88US=> NXXMZ2lZW0GQR1XS
CESS NIfBOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljGTWM2OD12ND6yNlMzKM7:TR?= MY\TRW5ITVJ?
RS4-11 MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rUPGlEPTB;NEmuNFk{QCEQvF2= NEfGXVlUSU6JRWK=
MS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfsTWM2OD13MD65N|UyKM7:TR?= M{ja[3NCVkeHUh?=
CTV-1 NGC0TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVzLkC3OEDPxE1? M3mzcXNCVkeHUh?=
D-502MG M2PNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDJWldJUUN3ME21NU43OjdzIN88US=> Mn7VV2FPT0WU
ML-2 NYjsc2VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e2d2lEPTB;NUKuPVE6PSEQvF2= MYnTRW5ITVJ?
SK-NEP-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTV|LkO5NlMh|ryP NFfwT5pUSU6JRWK=
LOXIMVI MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzy[|JKSzVyPUWzMlU5QDRizszN MnnZV2FPT0WU
DJM-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDBTWM2OD13Nj6zN|kyKM7:TR?= MUXTRW5ITVJ?
GI-1 NXvqcWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDuTWM2OD13Nj62NVQ6KM7:TR?= NUHIb3c5W0GQR1XS
IST-MES1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j5[GlEPTB;NkCuOVQ6OyEQvF2= M1vS[nNCVkeHUh?=
MV-4-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jiZ2lEPTB;NkCuOlU{QCEQvF2= MonPV2FPT0WU
OVCAR-4 M1jjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\USGlEPTB;NkOuOVY2PyEQvF2= M1H3U3NCVkeHUh?=
KE-37 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofLTWM2OD14Nj6yOlY5KM7:TR?= MlzXV2FPT0WU
D-542MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe0fXBXUUN3ME22PE41OTN3IN88US=> NUCzb2VjW0GQR1XS
MHH-PREB-1 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTd{Lki0OFEh|ryP MU\TRW5ITVJ?
MRK-nu-1 NV30fnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfxU|Z3UUN3ME23N{41PzB3IN88US=> NEPaTndUSU6JRWK=
D-247MG M{C3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfPT3dyUUN3ME23N{42PDR{IN88US=> NF33SHNUSU6JRWK=
OCI-AML2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzGU5BKSzVyPUe2Mlk{PjlizszN NYfZOldXW0GQR1XS
LP-1 NIfQVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnkbmdKSzVyPUiyMlg4OzFizszN MmTqV2FPT0WU
HCC1599 NGPKdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG5SXpsUUN3ME24OE4zQDN5IN88US=> MlToV2FPT0WU
KARPAS-45 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\NTWM2OD16ND62PVkzKM7:TR?= M2nienNCVkeHUh?=
BE-13 NGPMOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrFeoFKUUN3ME25PU4xPDd5IN88US=> M2DLbnNCVkeHUh?=
GCIY M4raRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TYfmlEPTB;OUmuNFk2PCEQvF2= MWrTRW5ITVJ?
BV-173 M1HmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHQT4JoUUN3ME2xNFAvOzJ3IN88US=> MlPxV2FPT0WU
LB2518-MEL MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFyMD63PFkh|ryP NFWwc|BUSU6JRWK=
KS-1 NFLuT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rsemlEPTB;MUCxMlY{QSEQvF2= M4T1RnNCVkeHUh?=
MOLT-16 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HuSGlEPTB;MUC0Mlk5PiEQvF2= NVm2cIlNW0GQR1XS
NCI-H1770 NFjhXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ntXmlEPTB;MUC4Mlc5PCEQvF2= M4S4WnNCVkeHUh?=
NCI-H82 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\CU|FKSzVyPUGxNE46PzZizszN M{DkdnNCVkeHUh?=
NCCIT NW\0NItYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFzMj61Nlkh|ryP MYTTRW5ITVJ?
KALS-1 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj6OZdjUUN3ME2xNVUvQTRzIN88US=> M2fwdnNCVkeHUh?=
LB2241-RCC M37sdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW4VnVKSzVyPUGxOk43PzlizszN M3r3WXNCVkeHUh?=
HH MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFzNz6zPVUh|ryP M{LXc3NCVkeHUh?=
HD-MY-Z M4THO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jLOmlEPTB;MUG4MlQ5QCEQvF2= NIf4PHBUSU6JRWK=
EB-3 NEL0SnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF{Mz6wPVQh|ryP MmTGV2FPT0WU
BL-70 NYrST3pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLQTWM2OD1zMkOuNVI4KM7:TR?= Mmi3V2FPT0WU
K-562 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjCZW1KSzVyPUGyOk4zPDVizszN M2fDOXNCVkeHUh?=
HT-144 M4jFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfQTWM2OD1zM{OuNVY1KM7:TR?= M3z4bHNCVkeHUh?=
PF-382 NVi4OG9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrxTZFKSzVyPUGzOE4{PjFizszN M1z3T3NCVkeHUh?=
RPMI-8226 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTlZ5I1UUN3ME2xN|UvODR3IN88US=> MXTTRW5ITVJ?
NCI-H1355 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF|NT61PFch|ryP NIrEZVJUSU6JRWK=
LXF-289 NH3UTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf6Z3o1UUN3ME2xN|kvPzhzIN88US=> NVXRXplkW0GQR1XS
NCI-H69 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTuTWM2OD1zNEKuPVMzKM7:TR?= M3TreHNCVkeHUh?=
SK-MEL-1 NFrrSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTx[otKSzVyPUG0O{4yOyEQvF2= M3rsU3NCVkeHUh?=
KARPAS-299 NFnjT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF2OT6xNkDPxE1? NIHDZnRUSU6JRWK=
GB-1 M4r0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy5W|dpUUN3ME2xOFkvOzJ{IN88US=> NVLVNnR5W0GQR1XS
CMK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3hTWM2OD1zNEmuOVE2KM7:TR?= MlnFV2FPT0WU
MPP-89 NXrr[IF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTLTWM2OD1zNU[uNFM2KM7:TR?= MlLTV2FPT0WU
KU812 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnUbIZxUUN3ME2xOlEvQTB{IN88US=> MYXTRW5ITVJ?
REH NGe1VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fRO2lEPTB;MU[yMlEzPSEQvF2= NWnG[XJqW0GQR1XS
NEC8 NXLnXpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnzTlRKSzVyPUG2OU4xOjZizszN M2XtcXNCVkeHUh?=
KP-N-YS MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEftNoRKSzVyPUG2PE4{QTVizszN NYW5cY9ZW0GQR1XS
Ramos-2G6-4C10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHIN4h2UUN3ME2xOlkvQTF3IN88US=> NF;HeXBUSU6JRWK=
Becker MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XZ[GlEPTB;MUe0MlE5KM7:TR?= M{O4V3NCVkeHUh?=
LB647-SCLC MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPjTWM2OD1zN{WuPFQ2KM7:TR?= NXjWR3E{W0GQR1XS
LU-139 NG\CWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjTeHhKSzVyPUG3PE4xOTlizszN MknqV2FPT0WU
QIMR-WIL NEPTSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCzfJh4UUN3ME2xO|kvPjR4IN88US=> M{HTZnNCVkeHUh?=
NCI-H1395 NV\JR5V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XORWlEPTB;MUe5Mlk6PiEQvF2= NUHUe4NTW0GQR1XS
NOMO-1 NIrNZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3nfoRKSzVyPUG4Nk45PSEQvF2= Ml74V2FPT0WU
GI-ME-N M2DYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHmTWM2OD1zOEeuPVY6KM7:TR?= NIjaS|JUSU6JRWK=
KMS-12-PE NV3LeGdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnCZZJbUUN3ME2xPFkvOjd|IN88US=> NUjLU|I6W0GQR1XS
Daudi NUPWVIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrrbVBKSzVyPUG5NU4yOjhizszN M2HuOXNCVkeHUh?=
LB996-RCC M4fUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\qWWRKSzVyPUG5NU43QTlizszN M1i1U3NCVkeHUh?=
NCI-H2107 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jocWlEPTB;MUmzMlc{QSEQvF2= MVrTRW5ITVJ?
SK-PN-DW NH3WU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXDTWM2OD1zOUSuO|E6KM7:TR?= MonEV2FPT0WU
MC-CAR MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSwTWM2OD1{MEKuNlU{KM7:TR?= Mm\mV2FPT0WU
SNB75 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ{MT65OEDPxE1? MknGV2FPT0WU
ES4 NVK4N4dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O5S2lEPTB;MkKzMlc5OyEQvF2= MWPTRW5ITVJ?
KARPAS-422 NXG3VIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzIOXQ2UUN3ME2yNlgvOzV{IN88US=> MmS3V2FPT0WU
NCI-H1648 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ{OT60PFkh|ryP NYL4UmZ3W0GQR1XS
ES6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ|OT60N{DPxE1? M1W4bXNCVkeHUh?=
KNS-81-FD NGrEZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLVT3pYUUN3ME2yOFEvOTl5IN88US=> M3\UfHNCVkeHUh?=
JAR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ3Nj6yNlUh|ryP NVHtUoRWW0GQR1XS
NB1 NWnUWINVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHJ[29SUUN3ME2yOlAvPTF4IN88US=> M1HuXXNCVkeHUh?=
D-336MG NETMfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXTNmZEUUN3ME2yOlAvPjl6IN88US=> Ml:yV2FPT0WU
BC-3 NH7oWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJ4NT6xO|gh|ryP MlfPV2FPT0WU
HCC2218 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3sbVNKSzVyPUK2Ok41OTVizszN Ml3mV2FPT0WU
TE-9 NYDXUmw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonxTWM2OD1{Nk[uOlI4KM7:TR?= MWrTRW5ITVJ?
LB1047-RCC NYLpOmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq5Z|BKSzVyPUK2Ok44PTNizszN MVjTRW5ITVJ?
CTB-1 NIPVboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ4OT65O|Mh|ryP NV;NfnpOW0GQR1XS
NB7 NXfMc3pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHzTWM2OD1{N{Gg{txO MUXTRW5ITVJ?
ST486 NI\1coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJ5Nz60NVIh|ryP MUfTRW5ITVJ?
HCC1187 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;iTWM2OD1{OEKuPFEyKM7:TR?= NFzqTodUSU6JRWK=
NCI-SNU-16 NUfUd5pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHUTWM2OD1{OESuNlQ5KM7:TR?= MYDTRW5ITVJ?
COR-L279 NXzOdJlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLPTWM2OD1{OUGuOVg1KM7:TR?= M1LNVXNCVkeHUh?=
ES8 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3yS4k4UUN3ME2yPVQvOTh{IN88US=> MofCV2FPT0WU
U-698-M MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnmPXZKSzVyPUK5PE4zPDNizszN NXvt[pl4W0GQR1XS
HEL NGn1R2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfxSVRsUUN3ME2zNFkvOTR7IN88US=> MUHTRW5ITVJ?
KINGS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX0[GlKSzVyPUOxNE43PzRizszN MkDTV2FPT0WU
KY821 M2D6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3nfWpKSzVyPUOzOk42QTVizszN NV3GOnlkW0GQR1XS
MZ1-PC Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnafnNkUUN3ME2zOFUvPjF6IN88US=> NYHXXlFCW0GQR1XS
LS-411N NWDUeFFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN3ND62OkDPxE1? MlTxV2FPT0WU
SIG-M5 NH7Od|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn4THpKSzVyPUO1PU44QDJizszN MVTTRW5ITVJ?
HT NGrJRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXDSplKSzVyPUO2O{44OTFizszN MWHTRW5ITVJ?
HC-1 NEfEe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXwbWFKSzVyPUO2O{44QDdizszN MnvqV2FPT0WU
NCI-H1694 NIPpTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjYO3ROUUN3ME2zO|IvQTN2IN88US=> MX3TRW5ITVJ?
BB65-RCC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnMOYlnUUN3ME2zO|YvOjR3IN88US=> MkS2V2FPT0WU
HAL-01 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN5OT64N|gh|ryP NEO3T4xUSU6JRWK=
ARH-77 NEPHXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSxTWM2OD1|OUSuNFA5KM7:TR?= NEPadmRUSU6JRWK=
MZ7-mel NFTNTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknlTWM2OD1|OUeuNlM{KM7:TR?= M3q5N3NCVkeHUh?=
SIMA MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu5TWM2OD12MEOuPVM{KM7:TR?= MkDlV2FPT0WU
DG-75 M{LPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKwS5hKSzVyPUSxOU43QThizszN NYHrOWVtW0GQR1XS
HUTU-80 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7XUmhNUUN3ME20NVkvOTh3IN88US=> M2niWXNCVkeHUh?=
KNS-42 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\UUWlEPTB;NEK1MlgyPSEQvF2= NF7zV3dUSU6JRWK=
SH-4 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV63N2NMUUN3ME20NlcvPTZ3IN88US=> Mm\jV2FPT0WU
L-540 NEHl[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTtTWM2OD12M{GuNFMyKM7:TR?= MWDTRW5ITVJ?
NB10 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LLR2lEPTB;NESxMlI{PCEQvF2= NF\uT41USU6JRWK=
ES1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL6O4g5UUN3ME20OVIvPzV|IN88US=> Mmi4V2FPT0WU
KMOE-2 M2HqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTR3Nj63NVEh|ryP Mlq5V2FPT0WU
MC116 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjvZok{UUN3ME20OVgvOTF4IN88US=> NHLY[pVUSU6JRWK=
RCC10RGB NEjEPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y3R2lEPTB;NE[wMlAxPSEQvF2= NV\lNItQW0GQR1XS
RL95-2 NESzW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3naXGlEPTB;NE[wMlI{PyEQvF2= NGraOnRUSU6JRWK=
Raji NYj0dIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTR4OD6xOFMh|ryP MnXiV2FPT0WU
CAS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjTcohKSzVyPUS3Nk4xPzNizszN NVzFSJVFW0GQR1XS
Calu-6 NGe1e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe4TWM2OD12N{WuNlY2KM7:TR?= Mm\2V2FPT0WU
KG-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTR5OD60OEDPxE1? MX\TRW5ITVJ?
LB771-HNC NYLF[HVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;DSWlEPTB;NEiyMlI{OiEQvF2= Mlj4V2FPT0WU
ACN NWnkTYNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnDRlZKSzVyPUS5N{42QTlizszN MlXvV2FPT0WU
KM12 M3PQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuwN3k4UUN3ME20PVYvPTh7IN88US=> MUfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID